GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Psychemedics Corp (NAS:PMD) » Definitions » EV-to-EBIT

Psychemedics (Psychemedics) EV-to-EBIT

: -5.20 (As of Today)
View and export this data going back to 1987. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Psychemedics's Enterprise Value is $15.20 Mil. Psychemedics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.92 Mil. Therefore, Psychemedics's EV-to-EBIT for today is -5.20.

The historical rank and industry rank for Psychemedics's EV-to-EBIT or its related term are showing as below:

PMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -87.52   Med: 12.59   Max: 811.32
Current: -5.2

During the past 13 years, the highest EV-to-EBIT of Psychemedics was 811.32. The lowest was -87.52. And the median was 12.59.

PMD's EV-to-EBIT is ranked worse than
100% of 109 companies
in the Medical Diagnostics & Research industry
Industry Median: 19.2 vs PMD: -5.20

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Psychemedics's Enterprise Value for the quarter that ended in Dec. 2023 was $17.52 Mil. Psychemedics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.92 Mil. Psychemedics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -16.67%.


Psychemedics EV-to-EBIT Historical Data

The historical data trend for Psychemedics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psychemedics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.40 -5.65 202.73 -24.64 -6.00

Psychemedics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.64 -17.99 -15.95 -10.09 -6.00

Competitive Comparison

For the Diagnostics & Research subindustry, Psychemedics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psychemedics EV-to-EBIT Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Psychemedics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Psychemedics's EV-to-EBIT falls into.



Psychemedics EV-to-EBIT Calculation

Psychemedics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15.196/-2.92
=-5.20

Psychemedics's current Enterprise Value is $15.20 Mil.
Psychemedics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psychemedics  (NAS:PMD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Psychemedics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-2.92/17.51976
=-16.67 %

Psychemedics's Enterprise Value for the quarter that ended in Dec. 2023 was $17.52 Mil.
Psychemedics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psychemedics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Psychemedics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Psychemedics (Psychemedics) Business Description

Traded in Other Exchanges
N/A
Address
289 Great Road, Suite 200, Acton, MA, USA, 01720
Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. Geographically it generates the majority of its revenue from the United States.
Executives
Shannon Shoemaker officer: Chief Revenue Officer 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Charles M Doucot officer: Executive Vice President 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Andrew Reynolds director C/O FLEETMATICS, 1100 WINTER STREET, 4TH FL, WALTHAM MA 02451
Brian Hullinger director, officer: President & CEO 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Robyn C Davis director ONE WALLINGFORD ROAD, MARBLEHEAD MA 01945
Michael Weisenhoff other: Assistant Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Michael I Schaffer officer: VP of Laboratory Operations C/O PAYCHEMEDICS CORP, 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
William B. Norris other: Assistant Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Darius G Nevin other: See Footnote 1 C/O WCI COMMUNITIES, INC., 24301 WALDEN CENTER DRIVE, BONITA SPRINGS FL 34134
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Andrew Limbek officer: Vice President & Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Fred J Weinert director 330 E MAIN ST, BARRINGTON IL 60620
Kubacki Raymond C Jr director, officer: Chairman, CEO & President 125 NAGOG PARK, ACTON MA 01720
A Clinton Allen director, officer: Chairman 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
Neil Lerner officer: VP - Finance C/O PSYCHEMEDICS CORPORATION, 125 NAGOG PARK, ACTON MA 01720